JBJulie Bossuyt

Julie Bossuyt

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Julie Bossuyt has a total of 183 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    S-nitrosylation of CaMKII Cys273 suppresses CaMKII Activation and Translocation within Cardiac Myocytes

    by Chidera C. Alim, Christopher Y. Ko, Julie Bossuyt, Donald M. Bers

    Calcium/calmodulin‑dependent protein kinase II delta (CaMKIIδ) is a central regulator of cardiac excitation–contraction coupling and is chronically activated in multiple cardiac pathologies. Nitrosylation has been implicated in cardiac cell signaling and function in health and disease. We tested how S-nitrosylation at two known CaMKII sites alters kinase activation conformation and mobility. In intact cardiomyocytes, we monitored in real time, the activation state with GSNO treatment– before or after activation of CaMKII. Active CaMKII conformation was assessed using the fluorescent biosensor Camui and fluorescence lifetime values, and mobility was assessed by fluorescence recovery after photobleach (FRAP) in CaMKII-GFP. To test the influence of each known S-nitrosylation site we used CaMKII in which each site was mutated (Cys273Ser and Cys290Ala) in Camui and CaMKII-GFP. The results show for the first time in intact ventricular cardiomyocytes, that S-nitrosylation of CaMKII at Cys273 prior to electrical field stimulation (and β-adrenergic agonists), suppresses CaMKIIδ activation, and mobility, effects largely lost in Cys273Ser CaMKIIδ. In contrast S-nitrosylation of CaMKIId Cys290 was critical for GSNO-induced activation and mobility. Thus, baseline S-nitrosylation at Cys273 limits CaMKIIδ activation and mobility, while S-nitrosylation at C290 when the kinase is activated enhances activation and mobility.

  • Open Access

    Empagliflozin restores cardiac function in obese-diabetic HFpEF mice but further alters gene expression

    by Juliana Mira Hernandez, Logan R. J. Bailey, Victoria R. Salemme, Christopher Y. Ko, Erin Y. Shen, Megan Ngim, Duong T. Hoang, Melissa Corea, Julie Bossuyt, Jennifer M. Davis, et al.

    Effective treatments for heart failure with preserved ejection fraction (HFpEF) are limited. Empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, provides cardiovascular benefits for patients with HFpEF. SGLT2 expression is virtually absent in cardiomyocytes, hence the exact protective mechanism of empagliflozin is unclear. We aimed to study the effect of in vivo empagliflozin treatment on excitation–contraction coupling (ECC), electrophysiology, and gene transcription in a translational two-hit HFpEF mouse model that combines the obese-diabetic leptin receptor-deficient db/db mice with chronic aldosterone infusion ( db/db + Aldo). We performed morphometry, echocardiography, cardiomyocyte electrophysiology, intracellular Ca 2+ imaging, and whole-heart RNA-sequencing in empagliflozin-treated db/db + Aldo and vehicle control mice. In db/db + Aldo mice, empagliflozin (in vivo, 4 weeks) reduced the elevated plasma blood glucose (13 ± 5 mmol/L versus 23 ± 8 mmol/L) and BNP levels, prevented pulmonary congestion, and ameliorated diastolic dysfunction. However, empagliflozin did not reduce cardiac hypertrophy and obesity. In healthy control mice, empagliflozin had no functional effect. Chronic in vivo empagliflozin treatment in db/db + Aldo also normalized the changes in cardiomyocyte electrophysiology and Ca 2+ handling properties measured in the absence of empagliflozin in the perfusion solution during cell experiments, indicating a true phenotypic rescue. Differentially expressed gene clusters were identified characteristic of the db/db genotype, aldosterone, and empagliflozin treatments. Interestingly, empagliflozin did not just reverse the HFpEF-altered gene expression but shifted it further away from control to a new expression profile. We conclude that chronic in vivo empagliflozin treatment restores cardiomyocyte electrophysiological and ECC properties, ameliorates diastolic function in cardiometabolic HFpEF, and induces complex gene expression changes.


  • Open Access

    Phosphoinositide Depletion and Compensatory Phospho-Signaling in Angiotensin II-Induced Heart Disease

    by Maartje Westhoff, Taylor L. Voelker, Silvia G. Del Villar, Phung N. Thai, Hannah M. Voorhees, Fatin Fazrina Roslan, Jody L. Martin, Julie Bossuyt, Padmini Sirish, Nipavan Chiamvimonvat, et al.

    BACKGROUND: Contractile dysfunction, hypertrophy, and cell death during heart failure are linked to altered Ca 2+ handling and elevated levels of the hormone AngII (angiotensin II), which signals through G q (Guanine nucleotide-binding protein alpha subunit q)-coupled AT 1 Rs (AngII type 1 receptors), initiating hydrolysis of phosphatidylinositol (4,5)-bisphosphate. Chronic elevation of AngII contributes to cardiac pathology, but the mechanisms linking sustained AngII signaling to heart dysfunction remain incompletely understood. Here, we demonstrate that chronic AngII exposure profoundly disrupts cardiac phosphoinositide homeostasis, triggering a cascade of cellular adaptations that ultimately impair cardiac function. METHODS: Mice received 1-week infusions of AngII, bisperoxovanadium (1,10 phenanthroline), both, or saline via osmotic minipumps. We used mass spectrometry, super-resolution microscopy, electrophysiology, confocal imaging, immunoblot, echocardiography, and histology to assess phosphoinositide levels, L-type voltage-gated calcium channel Ca V 1.2 localization, Ca 2+ handling, protein phosphorylation, cardiac function, and fibrosis. RESULTS: Chronic AngII infusion caused widespread phosphoinositide imbalance, reducing phosphatidylinositol, phosphatidylinositol phosphate, phosphatidylinositol bisphosphate, and phosphatidylinositol (3,4,5)-trisphosphate levels. Ca V 1.2 channels were partially redistributed from t-tubules to endosomal compartments. Despite reduced sarcolemmal channel expression, Ca 2+ currents and transients were maintained through enhanced PKA (protein kinase A)–mediated and CaMKII (Ca 2+ /calmodulin-dependent protein kinase II)–mediated phosphorylation of Ca 2+ -handling proteins. However, this compensation proved insufficient as cardiac function progressively declined, marked by pathological hypertrophy, t-tubule disruption, and diastolic dysfunction. PTEN (phosphatase and tensin homolog) inhibition preserved Akt signaling and protected against cardiac dysfunction and fibrosis without preventing cellular remodeling or altered calcium handling. CONCLUSIONS: These findings reveal a complex interplay between phosphoinositide signaling, ion channel trafficking, and compensatory phospho-regulation in AngII-induced cardiac pathology. We establish phosphatidylinositol (3,4,5)-trisphosphate depletion as a critical link between chronic AngII signaling and cardiac dysfunction. The dissociation between persistent cellular remodeling and preserved organ function with PTEN inhibition reveals that cardioprotection occurs primarily through reduced fibrosis. PTEN inhibition, thus, emerges as a promising therapeutic strategy for heart failure associated with pathological renin-angiotensin system activation, with potential to complement existing therapies by targeting antifibrotic responses.


  • Top Cited Papers

    Excitation-contraction coupling, cardiomyocyte electrophysiology, and transcriptome profiles in two HFpEF murine models: etiology and sex-dependent differences

    by Bence Hegyi, Logan R. J. Bailey, Juliana Mira Hernandez, Christopher Y. Ko, Erin Y. Shen, Julie Bossuyt, Jennifer M. Davis, Donald M. Bers

    Excitation-Ca 2+ signaling-contraction coupling (ECC) mechanisms are fundamental to heart function. ECC mechanisms are differentially altered in murine models of heart failure with preserved ejection fraction (HFpEF) by dominant disease pathology and sex. Diastolic dysfunction is more pronounced in diabetic-obese HFpEF mice (worse in females) than in hypertensive-obese HFpEF mice (female sex is protective). Diabetic-obese mice and primarily hypertensive-obese HFpEF mice exhibit differential ECC alterations and largely distinctive transcription changes, providing mechanistic insights into HFpEF sub-phenogroups.


  • Open Access

    Differential sex-dependent susceptibility to diastolic dysfunction and arrhythmia in cardiomyocytes from obese diabetic heart failure with preserved ejection fraction model

    by Juliana Mira Hernandez, Erin Y Shen, Christopher Y Ko, Zaynab Hourani, Emily R Spencer, Daria Smoliarchuk, Julie Bossuyt, Henk Granzier, Donald M Bers, Bence Hegyi

    Sex differences in heart failure with preserved ejection fraction (HFpEF) are important, but key mechanisms involved are incompletely understood. While animal models can inform about sex-dependent cellular and molecular changes, many previous pre-clinical HFpEF models have failed to recapitulate sex-dependent characteristics of human HFpEF. We tested for sex differences in HFpEF using a two-hit mouse model (leptin receptor–deficient db/db mice plus aldosterone infusion for 4 weeks; db/db + Aldo). We performed echocardiography, electrophysiology, intracellular Ca2+ imaging, and protein analysis. Female HFpEF mice exhibited more severe diastolic dysfunction in line with increased titin N2B isoform expression and PEVK element phosphorylation and reduced troponin-I phosphorylation. Female HFpEF mice had lower BNP levels than males despite similar comorbidity burden (obesity, diabetes) and cardiac hypertrophy in both sexes. Male HFpEF mice were more susceptible to cardiac alternans. Male HFpEF cardiomyocytes (vs. female) exhibited higher diastolic [Ca2+], slower Ca2+ transient decay, reduced L-type Ca2+ current, more pronounced enhancement of the late Na+ current, and increased short-term variability of action potential duration (APD). However, male and female HFpEF myocytes showed similar downregulation of inward rectifier and transient outward K+ currents, APD prolongation, and frequency of delayed afterdepolarizations. Inhibition of Ca2+/calmodulin-dependent protein kinase II (CaMKII) reversed all pathological APD changes in HFpEF in both sexes, and empagliflozin pre-treatment mimicked these effects of CaMKII inhibition. Vericiguat had only slight benefits, and these effects were larger in HFpEF females. We conclude that the db/db + Aldo pre-clinical HFpEF murine model recapitulates key sex-specific mechanisms in HFpEF and provides mechanistic insights into impaired excitation–contraction coupling and sex-dependent differential arrhythmia susceptibility in HFpEF with potential therapeutic implications. In male HFpEF myocytes, altered Ca2+ handling and electrophysiology aligned with diastolic dysfunction and arrhythmias, while worse diastolic dysfunction in females may depend more on altered myofilament properties.


  • Cardiac Protein Kinase D1 ablation alters the myocytes β-adrenergic response

    by Juliana Mira Hernandez, Christopher Y. Ko, Avery R. Mandel, Erin Y. Shen, Sonya Baidar, Ashley R. Christensen, Kim Hellgren, Stefano Morotti, Jody L. Martin, Bence Hegyi, et al.


  • Open Access

    Diabetes and Excess Aldosterone Promote Heart Failure With Preserved Ejection Fraction

    by Bence Hegyi, Juliana Mira Hernandez, Christopher Y. Ko, Junyoung Hong, Erin Y. Shen, Emily R. Spencer, Daria Smoliarchuk, Manuel F. Navedo, Donald M. Bers, Julie Bossuyt

    Background: The pathobiology of heart failure with preserved ejection fraction (HFpEF) is still poorly understood, and effective therapies remain limited. Diabetes and mineralocorticoid excess are common and important pathophysiological factors that may synergistically promote HFpEF. The authors aimed to develop a novel animal model of HFpEF that recapitulates key aspects of the complex human phenotype with multiorgan impairments. Methods and Results: The authors created a novel HFpEF model combining leptin receptor–deficient db/db mice with a 4‐week period of aldosterone infusion. The HFpEF phenotype was assessed using morphometry, echocardiography, Ca 2+ handling, and electrophysiology. The sodium‐glucose cotransporter‐2 inhibitor empagliflozin was then tested for reversing the arrhythmogenic cardiomyocyte phenotype. Continuous aldosterone infusion for 4 weeks in db/db mice induced marked diastolic dysfunction with preserved ejection fraction, cardiac hypertrophy, high levels of B‐type natriuretic peptide, and significant extracardiac comorbidities (including severe obesity, diabetes with marked hyperglycemia, pulmonary edema, and vascular dysfunction). Aldosterone or db/db alone induced only a mild diastolic dysfunction without congestion. At the cellular level, cardiomyocyte hypertrophy, prolonged Ca 2+ transient decay, and arrhythmogenic action potential remodeling (prolongation, increased short‐term variability, delayed afterdepolarizations), and enhanced late Na + current were observed in aldosterone‐treated db/db mice. All of these arrhythmogenic changes were reversed by empagliflozin pretreatment of HFpEF cardiomyocytes. Conclusions: The authors conclude that the db/db +aldosterone model may represent a distinct clinical subgroup of HFpEF that has marked hyperglycemia, obesity, and increased arrhythmia risk. This novel HFpEF model can be useful in future therapeutic testing and should provide unique opportunities to better understand disease pathobiology.


  • Open Access

    Nitrosylation of cardiac CaMKII at Cys290 mediates mechanical afterload‐induced increases in Ca2+ transient and Ca2+ sparks

    by Chidera C. Alim, Christopher Y. Ko, Juliana Mira Hernandez, Erin Y. Shen, Sonya Baidar, Ye Chen‐Izu, Donald M. Bers, Julie Bossuyt

    Cardiac mechanical afterload induces an intrinsic autoregulatory increase in myocyte Ca2+ dynamics and contractility to enhance contraction (known as the Anrep effect or slow force response). Our prior work has implicated both nitric oxide (NO) produced by NO synthase 1 (NOS1) and calcium/calmodulin‐dependent protein kinase II (CaMKII) activity as required mediators of this form of mechano‐chemo‐transduction. To test whether a single S‐nitrosylation site on CaMKIIδ (Cys290) mediates enhanced sarcoplasmic reticulum Ca2+ leak and afterload‐induced increases in sarcoplasmic reticulum (SR) Ca2+ uptake and release, we created a novel CRISPR‐based CaMKIIδ knock‐in (KI) mouse with a Cys to Ala mutation at C290. These CaMKIIδ‐C290A‐KI mice exhibited normal cardiac morphometry and function, as well as basal myocyte Ca2+ transients (CaTs) and β‐adrenergic responses. However, the NO donor S‐nitrosoglutathione caused an acute increased Ca2+ spark frequency in wild‐type (WT) myocytes that was absent in the CaMKIIδ‐C290A‐KI myocytes. Using our cell‐in‐gel system to exert multiaxial three‐dimensional mechanical afterload on myocytes during contraction, we found that WT myocytes exhibited an afterload‐induced increase in Ca2+ sparks and Ca2+ transient amplitude and rate of decline. These afterload‐induced effects were prevented in both cardiac‐specific CaMKIIδ knockout and point mutant CaMKIIδ‐C290A‐KI myocytes. We conclude that CaMKIIδ activation by S‐nitrosylation at the C290 site is essential in mediating the intrinsic afterload‐induced enhancement of myocyte SR Ca2+ uptake, release and Ca2+ transient amplitude (the Anrep effect). The data also indicate that NOS1 activation is upstream of S‐nitrosylation at C290 of CaMKII, and that this molecular mechano‐chemo‐transduction pathway is beneficial in allowing the heart to increase contractility to limit the reduction in stroke volume when aortic pressure (afterload) is elevated. image Key points: A novel CRISPR‐based CaMKIIδ knock‐in mouse was created in which kinase activation by S‐nitrosylation at Cys290 (C290A) is prevented. How afterload affects Ca2+ signalling was measured in cardiac myocytes that were embedded in a hydrogel that imposes a three‐dimensional afterload. This mechanical afterload induced an increase in Ca2+ transient amplitude and decay in wild‐type myocytes, but not in cardiac‐specific CaMKIIδ knockout or C290A knock‐in myocytes. The CaMKIIδ‐C290 S‐nitrosylation site is essential for the afterload‐induced enhancement of Ca2+ transient amplitude and Ca2+ sparks.


  • Open Access

    Protein Kinase D1 Regulates Cardiac Hypertrophy, Potassium Channel Remodeling, and Arrhythmias in Heart Failure

    by Julie Bossuyt, Johanna M. Borst, Marie Verberckmoes, Logan R. J. Bailey, Donald M. Bers, Bence Hegyi

    Background: Structural and electrophysiological remodeling characterize heart failure (HF) enhancing arrhythmias. PKD1 (protein kinase D1) is upregulated in HF and mediates pathological hypertrophic signaling, but its role in K+ channel remodeling and arrhythmogenesis in HF is unknown. Methods and Results: We performed echocardiography, electrophysiology, and expression analysis in wild‐type and PKD1 cardiomyocyte‐specific knockout (cKO) mice following transverse aortic constriction (TAC). PKD1‐cKO mice exhibited significantly less cardiac hypertrophy post‐TAC and were protected from early decline in cardiac contractile function (3 weeks post‐TAC) but not the progression to HF at 7 weeks post‐TAC. Wild‐type mice exhibited ventricular action potential duration prolongation at 8 weeks post‐TAC, which was attenuated in PKD1‐cKO, consistent with larger K+ currents via the transient outward current, sustained current, inward rectifier K+ current, and rapid delayed rectifier K+ current and increased expression of corresponding K+ channels. Conversely, reduction of slowly inactivating K+ current was independent of PKD1 in HF. Acute PKD inhibition slightly increased transient outward current in TAC and sham wild‐type myocytes but did not alter other K+ currents. Sham PKD1‐cKO versus wild‐type also exhibited larger transient outward current and faster early action potential repolarization. Tachypacing‐induced action potential duration alternans in TAC animals was increased and independent of PKD1, but diastolic arrhythmogenic activities were reduced in PKD1‐cKO. Conclusions: Our data indicate an important role for PKD1 in the HF‐related hypertrophic response and K+ channel downregulation. Therefore, PKD1 inhibition may represent a therapeutic strategy to reduce hypertrophy and arrhythmias; however, PKD1 inhibition may not prevent disease progression and reduced contractility in HF.


  • Open Access

    Subcellular Propagation of Cardiomyocyte β-Adrenergic Activation of Calcium Uptake Involves Internal β-Receptors and AKAP7

    by Thomas R Shannon, Dan J Bare, Sabine Van Dijk, Shayan Raofi, Tiffany N-M Huynh, Yang K Xiang, Julie Bossuyt, Kimberly L Dodge-Kafka, Kenneth S Ginsburg, Donald M Bers

    β-adrenergic receptor (β-AR) signaling in cardiac myocytes is central to cardiac function, but spatiotemporal activation within myocytes is unresolved. In rabbit ventricular myocytes, β-AR agonists or high extracellular [Ca] were applied locally at one end, to measure β-AR signal propagation as Ca−transient (CaT) amplitude and sarcoplasmic reticulum (SR) Ca uptake. High local [Ca]o, increased CaT amplitude under the pipette faster than did ISO, but was also more spatially restricted. Local isoproterenol (ISO) or norepinephrine (NE) increased CaT amplitude and SR Ca uptake, that spread along the myocyte to the unexposed end. Thus, local [Ca]i decline kinetics reflect spatio-temporal progression of β-AR end-effects in myocytes. To test whether intracellular β-ARs contribute to this response, we used β-AR-blockers that are membrane permeant (propranolol) or not (sotalol). Propranolol completely blocked NE-dependent CaT effects. However, blocking surface β-ARs only (sotalol) suppressed only ∼50% of the NE-induced increase in CaT peak and rate of [Ca]i decline, but these changes spread more gradually than NE alone. We also tested whether A-kinase anchoring protein 7γ (AKAP7γ; that interacts with phospholamban) is mobile, such that it might contribute to intracellular spatial propagation of β-AR signaling. We found AKAP7γ to be highly mobile using fluorescence recovery after photobleach of GFP tagged AKAP7γ, and that PKA activation accelerated AKAP7γ-GFP wash-out upon myocyte saponin-permeabilization, suggesting increased AKAP7γ mobility. We conclude that local β-AR activation can activate SR Ca uptake at remote myocyte sites, and that intracellular β-AR and AKAP7γ mobility may play a role in this spread of activation.